Abstract
An effective response to the COVID-19 pandemic requires identification of the factors that affect the severity and mortality of the disease. Previous nationwide studies have reported links between long-term PM2.5 concentrations and COVID-19 infection and mortality rates. In order to translate these results to the state level, we use Bayesian hierarchical models to explore potential links between long-term PM2.5 concentrations and census tract-level rates of COVID-19 outcomes (infections, hospitalizations, and deaths) in Colorado. We explicitly consider how the uncertainty in PM2.5 estimates affect our results by comparing four different PM2.5 surfaces from academic and governmental organizations. After controlling for 20 census tract level covariates including race/ethnicity, socioeconomic status, social distancing, age demographics, comorbidity rates, meteorology, and testing rate, we find that our results depend heavily on the choice of PM2.5 surface. Using PM2.5 estimates from the United States EPA, we find that a 1 µg/m3 increase in long term PM2.5 is associated with a statistically significant 25% increase in the relative risk of hospitalizations and a 35% increase in mortality. Results for all other surfaces and outcomes were not statistically significant. At the same time, we find a clear association between communities of color and COVID-19 outcomes at the Colorado census-tract level that is minimally affected by the choice of PM2.5 surface. A per-interquartile range (IQR) increase in the percent of non-African American people of color was associated with a 31%, 44%, and 59% increase in the relative risk of infection, hospitalization, and mortality respectively, while a per-IQR increase in the proportion of non-Hispanic African Americans was associated with a 4% and 7% increase in the relative risk of infections and hospitalizations. These results have strong implications for the implementation of an equitable public health response during the crisis and suggest targeted areas for additional air monitoring in Colorado.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Grant or Cooperative Agreement Number, 5 NUE1EH001346-04-00, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Colorado Department of Public Health and Environment(CDPHE) Institutional Review Board (IRB) and its policies allow for "self-determination" of human subjects research by CDPHE employees. The purpose of this memo is to outline the determination made by the project staff that the work conducted under the title "Long-term air pollution and other risk factors associated with COVID-19 at the census-tract-level in Colorado" constitutes "public health surveillance activities." In order to make its determination, project staff considered the following information: According to 45 CFR 46.102, "public health surveillance activities" are not "research" and thus, are not subject to the regulatory requirements of "human subjects research" at 45 CFR 46. The World Health Organization generally defines surveillance as "the continuous, systematic collection, analysis and interpretation of health-related data needed for the planning, implementation, and evaluation of public health practice." CDPHE is a "public health authority" as defined by the Health Insurance Portability and Accountability Act (HIPAA) as amended. As a "public health authority", CDPHE is responsible for public health matters in Colorado, including the conduct of public health surveillance. Colorado Revised Statutes at 25-1.5-102(b)(I) state: CDPHE has the powers and duties: "to investigate and monitor the spread of disease that is considered part of an emergency epidemic as defined in section 24-33.5-703", "to determine the extent of environmental contamination resulting from the emergency epidemic, and to rapidly provide epidemiological and environmental information...". The project is focused on COVID-19, the disease caused by infection of the SARS-CoV2 coronavirus, which is a communicable disease of pandemic proportion that requires urgent public health action. The project analyzes COVID-19 infection and severe outcome data, along with population statistics and environmental exposure data to identify risk factors associated with COVID-19 infection and severe outcome in Colorado. The project focuses on surveillance at the census tract level. However, Mr. Berg conducted this analysis as part of his COVID deployment duties, which also included processing individual-level data to various spatial aggregations and conducting other surveillance analyses. Therefore, Mr. Berg had access to a PII dataset including protected health information (PHI) for the COVID-19 outcomes in order to complete his assigned duties. The project is designed to provide insight into risk factors in Colorado and may not be indicative of factors influencing COVID infection and severe outcome in other states. The project is necessary to investigate and understand factors influencing the COVID outbreak in Colorado. The identification of risk factors for COVID-19 infection and severe outcome can directly impact Colorado's decision-making and actions such as identifying the need for greater social distancing in communities with greater risk factors or employing additional measures to decrease environmental exposures that may put communities at greater risk of COVID-19 infection and severe outcome.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
COVID-19 outcomes at the census-tract level cannot be released publically; however, other datasets are publicly available. All code to complete this analysis is available upon request to the project authors.
